<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02090439</url>
  </required_header>
  <id_info>
    <org_study_id>CHD 062-13</org_study_id>
    <nct_id>NCT02090439</nct_id>
  </id_info>
  <brief_title>Effectiveness of Silodosin in Medical Expulsive Therapy for Ureteral Pelvic Stone From 4 to 10 mm.</brief_title>
  <acronym>SiloMET</acronym>
  <official_title>Effectiveness of Silodosin in Medical Expulsive Therapy for Ureteral Pelvic Stone From 4 to 10 mm.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the diagnosis of renal colic gallstone , in addition to clinical and biological factors,&#xD;
      it is a key : medical imaging. Currently , the French recommendations require at least a&#xD;
      couple of Abdomen radiography Without Preparation lying face (ASP ) associated with abdominal&#xD;
      ultrasound . &quot;The abdominopelvic CT scan without injection of contrast is the examination of&#xD;
      choice.&#xD;
&#xD;
      Current recommendations in the management of gallstone colic simply based on the joint use of&#xD;
      analgesics , anti inflammatory drugs and control of water intake .&#xD;
&#xD;
      The mechanism of analgesic action of this treatment is a decrease in the pressure in the&#xD;
      cavities by decrease in diuresis and inflammation treatment of ureteral permitting passage of&#xD;
      urine . )&#xD;
&#xD;
      The expulsive medical therapy remains under evaluation. The French Association of Urology&#xD;
      does not recommend at this time for lack of evidence deemed sufficient.&#xD;
&#xD;
      For foreign companies Urology (EAU , AUA) , the use of calcium channel blockers or alpha&#xD;
      blockers in the treatment of symptomatic lower ureteral stones (4 to 10mm ) is recommended&#xD;
      (grade 1A) . However, there are less formal studies of their effectiveness .&#xD;
&#xD;
      Investigators wish to demonstrate the effectiveness of alpha in medical expulsive therapy for&#xD;
      pelvic stones 4 to 10mm .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Following difficulties in patient recruitment, we were forced to stop the study prematurely.&#xD;
  </why_stopped>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to expel kidney stone</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Kidney Stone</condition>
  <condition>Expulsive Medical Therapy</condition>
  <arm_group>
    <arm_group_label>standard treatment with Silodosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Silodosin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silodosin</intervention_name>
    <arm_group_label>standard treatment with Silodosin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men&#xD;
&#xD;
          -  Women on oral contraception (for women of childbearing age).&#xD;
&#xD;
          -  18 to 60 years.&#xD;
&#xD;
          -  First admission to the episode of renal colic without evidence of complication&#xD;
             (afebrile without renal input, negative beta-hCG (women of childbearing age) without&#xD;
             severe vomiting without uropathy malformation known underlying balance sheet. ).&#xD;
&#xD;
          -  In ability to deliver its consent.&#xD;
&#xD;
          -  patient with a single calculation pelvic ureteral 4 to 10 mm cross-sectional diameter,&#xD;
             with or without calyx calculations (not obstructive), but other calculation ureter.&#xD;
&#xD;
          -  Unique pelvic stone :&#xD;
&#xD;
          -  Proven by imaging: helical scan without contrast injection-ASP abdominopelvic.&#xD;
&#xD;
          -  Radio-opaque to the ASP.&#xD;
&#xD;
          -  More than 3mm and &lt;11mm (4 to 10 mm) of cross-sectional diameter.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women scalable&#xD;
&#xD;
          -  No oral contraception&#xD;
&#xD;
          -  Contraception by intrauterine device .&#xD;
&#xD;
          -  Concurrent infection ( positive urine test strip for Nitrites and / or general signs&#xD;
             tanks (T ° C &gt; 38 ° 5 or &lt;36 ° 5 or chills) .&#xD;
&#xD;
          -  Renal failure ( Creatinine clearance calculated by Cockcroft and Gault &lt;60 mL / min).&#xD;
&#xD;
          -  Single functional kidney .&#xD;
&#xD;
          -  Treatment with calcium channel blockers or alpha blockers.&#xD;
&#xD;
          -  Recent or upcoming cataract surgery .&#xD;
&#xD;
          -  Orthostatic hypotension .&#xD;
&#xD;
          -  A history of peptic ulcer disease , liver disease , allergy to paracetamol , the&#xD;
             ketoprofen .&#xD;
&#xD;
          -  History of stroke , heart disease, diabetes.&#xD;
&#xD;
          -  History of allergy to any treatment plans.&#xD;
&#xD;
          -  Refusal to enter the protocol.&#xD;
&#xD;
          -  Already included in the protocol.&#xD;
&#xD;
          -  Medication against -indicated in combination with NSAI (vitamin K ..)&#xD;
&#xD;
          -  Hepatic Impairment&#xD;
&#xD;
          -  Participation in other biomedical research&#xD;
&#xD;
          -  Patients with a history of hypersensitivity such as bronchospasm , asthma, rhinitis ,&#xD;
             urticaria&#xD;
&#xD;
          -  Patients with asthma associated with chronic rhinitis, chronic sinusitis and / or&#xD;
             nasal polyposis&#xD;
&#xD;
          -  History of gastrointestinal bleeding or perforation during previous treatment with&#xD;
             NSAI or history of gastrointestinal diseases such as ulcerative colitis, Crohn's&#xD;
             diseases, gastrointestinal bleeding , cerebrovascular bleeding or other bleeding&#xD;
             evolving&#xD;
&#xD;
          -  Patients receiving treatment associated may increase the risk of ulceration or&#xD;
             bleeding (glucocorticoids , selective serotonin reuptake inhibitors and antiplatelet&#xD;
             agents such as aspirin )&#xD;
&#xD;
          -  Patients with uncontrolled hypertension, congestive heart failure , ischemic heart&#xD;
             disease, peripheral arterial disease, and / or a history of stroke (including&#xD;
             transient ischemic attack)&#xD;
&#xD;
          -  Patients treated with potassium-sparing drugs&#xD;
&#xD;
        Pelvic stone :&#xD;
&#xD;
          -  Multiple&#xD;
&#xD;
          -  Size &lt; 4 mm or &gt; 10mm&#xD;
&#xD;
          -  Radiolucent&#xD;
&#xD;
          -  Not formally identified by imaging.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François LUYCKX, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD Vendée La Roche sur Yon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Loire Vendée Océan</name>
      <address>
        <city>Challans</city>
        <zip>85302</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier départemental Vendée</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>March 14, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2014</study_first_posted>
  <last_update_submitted>February 10, 2016</last_update_submitted>
  <last_update_submitted_qc>February 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silodosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

